Nemolizumab (Nemluvio)

What is nemolizumab?

Nemolizumab (Nemluvio) is an injectable biologic used in dermatology for prurigo nodularis and atopic dermatitis. It is especially notable for patients with severe itch, because it targets a pathway closely tied to the itch-inflammation cycle.

For many patients, itch is one of the hardest symptoms to control, so this medication is often discussed when scratching, nodules, poor sleep, or chronic itch have become major problems.

How does nemolizumab work?

Nemolizumab blocks signaling through the interleukin-31 receptor. IL-31 is strongly associated with itch and inflammation in certain skin diseases. By reducing this signaling, nemolizumab may help reduce itch and improve the secondary skin changes that develop from repeated scratching.

This makes it somewhat different from biologics that focus more broadly on eczema inflammation rather than specifically emphasizing the itch pathway.

What are possible side effects of nemolizumab?

Possible side effects can include:

  • Injection site reactions

  • Headache

  • Upper respiratory symptoms

  • Nausea in some patients

  • Eczema flares or skin irritation in some patients

As with other biologic medications, patients should review vaccination status, overall health history, and possible side effects with their clinician.

How is nemolizumab used?

Nemolizumab is given by injection on a schedule directed by your provider. Some patients may be able to administer it at home after training. It is stored in the refrigerator.

For eczema, it may be used along with topical treatment rather than replacing all topical therapy. For prurigo nodularis, it is often considered when itch and scratching remain difficult to control with more routine approaches.

THIS CONTENT IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES AND MAY NOT BE COMPREHENSIVE. IT DOES NOT CONSTITUTE MEDICAL ADVICE. PLEASE REFER TO OUR TERMS OF USE FOR FURTHER DETAILS. ALWAYS CONSULT WITH YOUR HEALTHCARE PROVIDER BEFORE MAKING ANY MEDICAL DECISIONS.